Peptide Targets for Glioblastoma Against Novel Cytomegalovirus Antigens
Clinical trial NCT02864368 · TERMINATED
Trial details
- NCT number
- NCT02864368
- Sponsor
- Eric Thompson, M.D.
- Status
- TERMINATED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2016-12-07
- Primary completion
- 2020-06-15
- Enrollment
- 27
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.